The preparation of flavin mononucleotide (FMN) and FMN analogs from their corresponding riboflavin precursors is traditionally performed in a two-step procedure. After initial enzymatic conversion of riboflavin to flavin adenine dinucleotide (FAD) by a bifunctional FAD synthetase, the adenyl moiety of FAD is hydrolyzed with snake venom phosphodiesterase to yield FMN. To simplify the protocol, we have engineered the FAD synthetase from Corynebacterium ammoniagenes by deleting its N-terminal adenylation domain. The newly created biocatalyst is stable and efficient for direct and quantitative phosphorylation of riboflavin and riboflavin analogs to their corresponding FMN cofactors at preparative-scale.
Introduction
Flavin monophosphate (FMN) and flavin adenine dinucleotide (FAD) constitute two important natural cofactors for one and two-electron transfer reactions. In their protein-bound forms, FMN and FAD are involved in numerous critical cellular functions including oxidative phosphorylation and photosynthesis, fatty acid oxidation, DNA metabolism, detoxification and biosynthesis of other cofactors (Joosten and van Berkel, 2007) where they facilitate a diverse set of chemistries including dehydrogenation, mono and dioxygenation, halogenation and reductions (Miura, 2001; Macheroux et al., 2011; de Gonzalo and Fraaije, 2013; Walsh and Wencewicz, 2013) . Both cofactors are synthesized from GTP and ribulose-5-phosphate via the common intermediate riboflavin (RF) (Bacher et al., 2000) . Subsequently, RF is converted to FMN and FAD through two consecutive reactions, an initial phosphorylation catalyzed by ATP:riboflavin 5 0 -phosphotransferase (EC 2.7.1.26), followed by adenylation facilitated by ATP:FMN adenyltransferase (E.C. 2.7.7.2) (Fig. 1) . Interestingly, eukaryotes possess separate riboflavin kinases (RFKs) and FMN adenyltransferases to catalyze these two reactions (Merrill and McCormick, 1980) . In contrast, prokaryotes utilize a bi-functional fusion protein (FADS) with an N-terminal adenylation domain and a C-terminal RFK domain (Hagihara et al., 1995) .
A series of crystal structures of eukaryotic and prokaryotic representatives have been solved. For the bi-functional FADSs, the structures of two enzymes from Thermotoga maritima (PDB access#: 1MRZ, 1T6X, 1T6Y, and 1T6Z (Wang et al., 2005; Shin et al., 2013) ) and Corynebacterium ammoniagenes (PDB access#: 2X0K (Herguedas et al., 2010) ; Fig. 1 ) were reported. A comparison of their N-terminal adenyl-transfer domain with its eukaryotic homologs indicates only low structural and sequence similarity. In contrast, the core structures of the RFKs have substantial overlap although differences exist in loop regions. Although there are a number of hydrogen bonding and hydrophobic interactions at the domain interface, Medina and coworkers demonstrated that each individual domain could be expressed in soluble form (Frago et al., 2008) . However, only the C-terminal RFK was catalytically active based on tests with crude cell extracts.
Prokaryotic FADS and eukaryotic RFKs have both been applied for the phosphorylation of RF to FMN in the laboratory. These enzymatic routes represent attractive alternatives to organic synthetic methods that require extra protection/ deprotection steps of the ribityl moiety to ensure regioselectivity (Hersh and Walsh, 1980) . In early studies, researchers employed either rat liver RFK (Merrill and McCormick, 1980) or FADS from Corynebacterium ammoniagenes (CaFADS) (Spencer et al., 1976) . The rat enzyme has the advantage of directly producing the desired mononucleotidic flavin product, yet requires a lengthy enzyme purification process and lacks stability which greatly limits its practical use as a biocatalyst. In contrast, the bifunctional CaFADS is a robust biocatalyst but complicates the synthesis as it directly converts RF to the corresponding FAD. Furthermore, technical difficulties arise with CaFADS when used at preparative scales since the adenylation step is subject to substrate inhibition and the reaction is reversible, producing a mixture of FMN and FAD (Efimov et al., 1998) . The preparation of FMN therefore requires extra purification and a second reaction step involving treatment of FAD with snake venom phosphodiesterase to cleave off the adenyl moiety. Despite these problems, the conversion of RF with CaFADS remains the standard procedure for in vitro synthesis of FMN (and FAD) today. A number of in vivo strategies have also been developed for the intracellular biosynthesis of FMN (Yatsyshyn et al., 2009; Krauss et al., 2011) , yet the in vitro enzymatic approach remain popular as it offers greater experimental versatility. More specifically, researchers can expand the scope of FMN synthesis beyond RF by exploiting the enzymes' substrate promiscuity which allows for effective conversion of naturally occurring and synthetic RF analogs (Murthy and Massey, 1997; Ghisla and Edmondson, 1999; Miller and Edmondson, 1999; Mack and Grill, 2006; Taylor et al., 2013) . Such flavin analogs are important functional probes. Substitutions in the isoalloxazine moiety as shown in Fig. 2 can, for example, modulate the redox potential of cofactors for alternate chemical reactivity or provide novel sites for covalent crosslinking of cofactor and enzyme (Walsh et al., 1978; Ghisla and Massey, 1986 ).
Motivated by a desire to create a stable RFK for the direct enzymatic phosphorylation of RF and its analogs, we herein describe the expression, purification and functional evaluation of a truncated C-terminal RFK domain from CaFADS. The engineered flavokinase was expressed heterologously in Escherichia coli in high yields and purified in one step via metal affinity chromatography. More importantly, we demonstrate that the isolated enzyme is an effective biocatalyst for the phosphorylation of RF and three flavin analogs 7,8-dichloro-riboflavin (1), Fig. 2 . Overview of modifications in the isoalloxazine moiety of flavin analogs used in this study. Besides the native substrate (RF), the engineered FADSs were tested with 7,8-dichloro riboflavin (1), 8-amino riboflavin (2) and 5-deaza riboflavin (3) to produce the corresponding monophosphate derivates (1a-3a). Herguedas et al., 2010) . With the help of ATP, the C-terminal phosphoryl-transfer domain (shown in blue) initially converts RF to FMN. The presumed active site is marked by two superimposed FMN structures (sticks) from aligned Thermotoga and human kinase homologs. PDB code: 1P4M (Karthikeyan et al., 2003) and 1T6Y (Shin et al., 2013) . Next, the N-terminal adenylation domain (highlighted in yellow) facilitates the ATP-driven conversion of FMN to flavin adenine dinucleotide (FAD).
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8-amino-riboflavin (2) and 5-deaza-riboflavin (3) to their corresponding FMN derivatives.
Results and discussion
Heterologous expression and purification of full-length and truncated FADSs
As part of our efforts to create an effective biocatalytic system for the direct phosphorylation of RF and analogs to their corresponding monophosphates, the two genes encoding for fulllength Ca FADS (amino acids 1 -338) and the truncated C-terminal RF kinase domain (tcRFK; amino acids 187-338) were cloned into a standard pET vector. Upon induction of heterologous protein expression, both enzymes could be produced in soluble form with high yields of typically 70 mg per liter of culture broth in E. coli. The subsequent protein purification involved a two-step procedure with initial ion-exchange chromatography, followed by gel filtration for final clean-up. The gel filtration step also doubled for the analysis of the proteins' quaternary structures. As previously reported, the elution profile of full-length FADS showed two characteristic peaks at molecular weights corresponding to its monomeric and trimeric forms (Herguedas et al., 2010) . In contrast, the tcRFK eluted as a single peak at an estimated molecular weight of 16.6 kDa, consistent with monomeric enzyme.
To assist in protein purification and simplify preparative-scale FMN synthesis by immobilization of the biocatalyst, we also tested the impact of an N or C-terminal poly-His tag on the stability and catalytic activity of tcRFK. Heterologous protein expression of both variants shows that the N-terminal tag was not tolerated by the truncated enzyme, resulting in protein aggregates with no detectable catalytic activity. In contrast, tcRFK with the C-terminal affinity tag (tcRFKhis) exhibits robust expression of soluble and active enzyme at levels comparable with full-length FADS.
While the deletion of the N-terminal domain of CaFADS might seem relatively straightforward, the principle cannot be applied to all bi-functional enzymes in this subfamily. We were unsuccessful in using the same strategy for the N-terminal truncation of the FADS from T. maritima. The crystal structures of the two FADSs are superimposable with an RMSD of 2.07Å (204 out of 266 amino acids; PDB access#: 1MRZ (Wang et al., 2005) & 2X0K (Herguedas et al., 2010) , even though they only share about 30% protein sequence identity. The high structural and functional similarity suggested that deletion of the N-terminal adenylation domain to TmFADS could yield a more thermostable RFK. While heterologous expression of the fulllength enzyme produced a functional biocatalyst with moderate catalytic activity for RF relative to CaFADS, attempts to generate a truncated version of the T. maritima protein resulted in mostly insoluble protein aggregates (data not shown).
Characterization of secondary structure and stability by circular dichroism spectroscopy Although high expression levels of soluble protein is a good indicator for the structural integrity of tcRFK and tcRFKhis, we studied their secondary structure composition by far-UV circular dichroism (CD) spectroscopy and quantitatively assessed their stability in thermodenaturation experiments. The far-UV spectra of the truncated variants showed a significant shift toward greater b-strand content compared with the typical mixed a/b structure spectrum of full-length FADS (Fig. 3) . The change is consistent with an analysis of the secondary structure elements assigned in the crystal structure of CaFADS. The bi-functional enzyme contains 11 a-helices and 22 b-strands, making up 28 and 29% of the 338-amino acid sequence, respectively. In contrast, the C-terminal domain of FADS which doubles as a model for tcRFK is considerably more b-strand rich, consisting of only one a-helix but eleven b-strands which shifts the percentages to 16 and 39% for the 151-residue protein, respectively. The experimentally observed changes in the far-UV CD spectra are consistent with such a predicted shift in secondary structure content.
Separately, we evaluated the stability of the full-length and truncated proteins via thermodenaturation in the CD spectrophotometer. Deletion of the N-terminal adenosyl transfer domain in the tcRFK variants results in a drop in the T M value from 408C (parental CaFADS) to 358C for tcRFK. The decline could at least in part be caused by the disruption of hydrogenbonding interactions and exposure of hydrophobic surface areas Fig. 3 . Far UV CD spectra and thermodenaturation data for full-length FADS (filled triangle), C-terminally truncated FADS (tcRFK, filled square) and His-tagged C-terminally truncated FADS (tcRFKhis, empty circle). For the thermodenaturation experiments, CD signal was measured at 222 nm from 10-808C and T M data was calculated based on nonlinear curve fit.
FAD synthetase for biocatalytic conversion of riboflavin and analogs to FMN at the domain interface. Addition of the C-terminal poly-His tag further reduces the T M to 308C, presumably due to the conformationally flexible tail formed by the extra amino acids. From a practical perspective, the lower temperature of unfolding for the tcRFK variants did not, however, impact the enzyme's application for FMN (analog) synthesis. Extended incubation of the biocatalyst in the Tris-HCl/MgCl 2 reaction buffer at temperatures from 20 to 378C did not result in a notable decline in activity. The discrepancy between CD and activity data can be explained by the switch in buffer salts from phosphate to Tris which is necessary due to limiting spectral properties and strong pH shifts associated with temperature change of Tris-HCl buffer.
Catalytic activity with RF and flavin analogs
Beyond the structural integrity of tcRFK, the catalytic properties of the truncated enzymes were first tested with RF. Product formation could easily be followed qualitatively by t.l.c. analysis while high performance liquid chromatography (HPLC) analysis of quenched reaction aliquots provided a quantitative measure for enzyme activity (Fig. 4) . Based on the HPLC data, the rate of conversion for RF phosphorylation to FMN by tcRFKhis under standard reaction conditions (see Materials and Methods section) was determined as 0.9 mM/min/mg of enzyme and reached . 95% completion ( Table I ). The measured rate compares well with the previously reported kinetic parameter for the full-length CaFADS (Herguedas et al., 2010) , suggesting that the deletion of the N-terminal domain does not alter the catalytic performance of our engineered RF kinase.
Besides phosphorylation of the natural substrate, we were particularly interested in the performance of tcRFKhis with RF analogs in order to establish a direct enzymatic route for preparing the corresponding FMN derivatives. To demonstrate the promiscuity of the engineered RF kinase, we tested three flavin analogs 7,8-dichloro-riboflavin (1), 8-amino-riboflavin (2) and 5-deaza-riboflavin (3) (Fig. 2) as substrates for tcRFKhis. As for the native substrate, the reactions were monitored by t.l.c. and HPLC and the identity of products was confirmed by spectrophotometric analysis and mass spectrometry (data not shown). The flavin analogs were effectively and completely converted (.95%) except for 3 where the reaction reach 90-95%. The reason for the incomplete reaction of 3 is unclear but could be caused by small amounts of contaminants from its chemical synthesis. The measured rates of conversion for all analogs are similar to or better than that for RF. The dichloro (1) and 8-amino (2) derivatives were turned over approximately three-and six-fold faster, respectively, while the 5-deaza analog (3) was phosphorylated at a rate comparable to the native substrate (Table I) . We associate these rate changes with actual gains in catalytic turnover. The high substrate concentration (50 mM to 0.5 mM) in our experiments relative to the reported K M value for RF of ,1 mM (Efimov et al., 1998) should more than compensate for possible differences in substate binding affinity.
Finally, the tcRFK variants were shown to function as robust biocatalysts for preparative-scale synthesis of FMN (analogs). Although substrate concentrations of .0.5 mM are problematic due to limited solubility of the RFs, the reaction was successfully scaled-up to 100 ml to enable conversion of milligram quantities typically required for laboratory experiments. To simplify product isolation and assist in the recovery of the biocatalyst, we chose to immobilize the tcRFKhis variant on Ni-NTA agarose. In experiments with the native RF and our three RF analogs, the performance of the immobilized enzyme was indistinguishable (monitored by t.l.c.) from the homogenous reactions at comparable enzyme loads.
In summary, tcRFK and tcRFKhis are two stable variants of the C-terminal domain from CaFADS. The truncated enzymes represent an efficient biocatalytic system for the phosphorylation of RFs, benefiting from the robustness and simple expression/ purification of the bacterial kinases while eliminating the need for two separate enzymatic reactions for the synthesis of FMN from RF via FAD. Furthermore, the substrate promiscuity of tcRFK makes these biocatalysts highly suitable for the phosphorylation of RF analogs to their corresponding FMN anabolites.
Supplementary data
Supplementary data (Materials and Methods) is available at PEDS online.
